Evidence map›Paper›PMID 34544665›Full record

ArticleHematology, transfusion and cell therapy

Functional polymorphisms of DNA repair genes in Latin America reinforces the heterogeneity of Myelodysplastic Syndrome.

Daniela de Paula Borges, Rinna Maria Arruda Rodrigues Dos Santos, Elvira Rodrigues Pereira Velloso, Howard Lopes Ribeiro Junior, Irene Beatriz Larripa, Maria Fernanda Camacho, Jacqueline González, Leandro Daniel Burgos Pratx, Sílvia Maria Meira Magalhães, Carolina Bárbara Belli and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Turkish journal of haematology : official journal of Turkish Society of Haematology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Daniela de Paula BorgesCancer Cytogenomic Laboratory, Universidade Federal do Ceara (UFC), Fortaleza, CE, Brazil; Post Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, CE, Brazil.
Rinna Maria Arruda Rodrigues Dos SantosCancer Cytogenomic Laboratory, Universidade Federal do Ceara (UFC), Fortaleza, CE, Brazil; Post Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, CE, Brazil.
Elvira Rodrigues Pereira VellosoHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
Howard Lopes Ribeiro JuniorCancer Cytogenomic Laboratory, Universidade Federal do Ceara (UFC), Fortaleza, CE, Brazil; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.
Irene Beatriz LarripaInstitute of Experimental Medicine (IMEX-CONICET)/ National Academy of Medicine, Buenos Aires, Argentina.
Maria Fernanda CamachoInstitute of Experimental Medicine (IMEX-CONICET)/ National Academy of Medicine, Buenos Aires, Argentina.
Jacqueline GonzálezHematology Center, Hospital General de Agudos Carlos Durant, Buenos Aires, Argentina.
Leandro Daniel Burgos PratxTransfusional Medicine, Italian Hospital of Buenos Aires, Buenos Aires, Argentina.
Sílvia Maria Meira MagalhãesCancer Cytogenomic Laboratory, Universidade Federal do Ceara (UFC), Fortaleza, CE, Brazil; Post Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, CE, Brazil.
Carolina Bárbara BelliInstitute of Experimental Medicine (IMEX-CONICET)/ National Academy of Medicine, Buenos Aires, Argentina.
Ronald Feitosa PinheiroCancer Cytogenomic Laboratory, Universidade Federal do Ceara (UFC), Fortaleza, CE, Brazil; Post Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, CE, Brazil. Electronic address: ronaldpinheiro@pq.cnpq.br.
Universidade Federal do Ceará · BRAcademia Nacional de Medicina · AREl Hospital General de Agudos Carlos G. Durand · ARHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHospital Italiano de Buenos Aires · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleotide excision repair pathway (NER) is an essential mechanism for single-strand breaks (SSB) repair while xeroderma pigmentosum family (XPA to XPG) is the most important system to NER. Myelodysplastic syndrome (MDS) is a heterogeneous hematological cancer characterized by cytopenias and risk of acute myeloid leukemia (AML) transformation. MDS pathogenesis has been associated with problems of DNA repair system. This report aimed to evaluate NER polymorphisms (XPA rs1800975, XPC rs2228000, XPD rs1799793 and XPF rs1800067) in 269 MDS patients of different populations in Latin America (173 Brazilian and 96 Argentinean). Genotypes were identified in DNA samples by RT-qPCR using TaqMan SNP Genotyping Assay. Regarding rs1799793 polymorphism of XPD for Brazilian population, the heterozygous genotype AG presented a high odds ratio (OR) to have a normal karyotype (p = 0.012, OR=3.000) and the mutant homozygous genotype AA was associated to a high OR of AML transformation (p = 0.034, OR=7.4). In Argentine population, the homozygous mutant AA genotype of rs1800975 polymorphism of XPA was associated with an increased odd to have hemoglobin levels below 8g/dL (p = 0.013, OR=10.000) while for the rs1799793 polymorphism of XPD, the heterozygous AG genotype decreased OR to be classified as good (p < 0.001, OR=9.05 × 10

Indexed as

DNA damageDNA repairFunctional polymorphismMyelodysplastic syndromeNER

Identifiers

PMID34544665
PMCPMC10244233
OpenAlexW3199188178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.